488 related articles for article (PubMed ID: 18197612)
41. Targeting heat shock response to sensitize cancer cells to proteasome and Hsp90 inhibitors.
Zaarur N; Gabai VL; Porco JA; Calderwood S; Sherman MY
Cancer Res; 2006 Feb; 66(3):1783-91. PubMed ID: 16452239
[TBL] [Abstract][Full Text] [Related]
42. Structure-based design of novel potent protein kinase CK2 (CK2) inhibitors with phenyl-azole scaffolds.
Hou Z; Nakanishi I; Kinoshita T; Takei Y; Yasue M; Misu R; Suzuki Y; Nakamura S; Kure T; Ohno H; Murata K; Kitaura K; Hirasawa A; Tsujimoto G; Oishi S; Fujii N
J Med Chem; 2012 Mar; 55(6):2899-903. PubMed ID: 22339433
[TBL] [Abstract][Full Text] [Related]
43. Potent cytotoxic C-11 modified geldanamycin analogues.
Tian ZQ; Wang Z; MacMillan KS; Zhou Y; Carreras CW; Mueller T; Myles DC; Liu Y
J Med Chem; 2009 May; 52(10):3265-73. PubMed ID: 19405528
[TBL] [Abstract][Full Text] [Related]
44. Hsp90 inhibitors and drugs from fragment and virtual screening.
Roughley S; Wright L; Brough P; Massey A; Hubbard RE
Top Curr Chem; 2012; 317():61-82. PubMed ID: 21647838
[TBL] [Abstract][Full Text] [Related]
45. New novobiocin analogues as antiproliferative agents in breast cancer cells and potential inhibitors of heat shock protein 90.
Le Bras G; Radanyi C; Peyrat JF; Brion JD; Alami M; Marsaud V; Stella B; Renoir JM
J Med Chem; 2007 Nov; 50(24):6189-200. PubMed ID: 17979263
[TBL] [Abstract][Full Text] [Related]
46. High-throughput screening assay for inhibitors of heat-shock protein 90 ATPase activity.
Rowlands MG; Newbatt YM; Prodromou C; Pearl LH; Workman P; Aherne W
Anal Biochem; 2004 Apr; 327(2):176-83. PubMed ID: 15051534
[TBL] [Abstract][Full Text] [Related]
47. Synthesis and biological activity of simplified denoviose-coumarins related to novobiocin as potent inhibitors of heat-shock protein 90 (hsp90).
Radanyi C; Le Bras G; Messaoudi S; Bouclier C; Peyrat JF; Brion JD; Marsaud V; Renoir JM; Alami M
Bioorg Med Chem Lett; 2008 Apr; 18(7):2495-8. PubMed ID: 18304811
[TBL] [Abstract][Full Text] [Related]
48. Synthesis and biological evaluation of 3,5-disubstituted-4-alkynylisoxozales as a novel class of HSP90 inhibitors.
Sun J; Lin C; Qin X; Dong X; Tu Z; Tang F; Chen C; Zhang J
Bioorg Med Chem Lett; 2015 Aug; 25(16):3129-34. PubMed ID: 26112442
[TBL] [Abstract][Full Text] [Related]
49. Development of novobiocin analogues that manifest anti-proliferative activity against several cancer cell lines.
Burlison JA; Avila C; Vielhauer G; Lubbers DJ; Holzbeierlein J; Blagg BS
J Org Chem; 2008 Mar; 73(6):2130-7. PubMed ID: 18293999
[TBL] [Abstract][Full Text] [Related]
50. Fragment-based hit discovery and structure-based optimization of aminotriazoloquinazolines as novel Hsp90 inhibitors.
Casale E; Amboldi N; Brasca MG; Caronni D; Colombo N; Dalvit C; Felder ER; Fogliatto G; Galvani A; Isacchi A; Polucci P; Riceputi L; Sola F; Visco C; Zuccotto F; Casuscelli F
Bioorg Med Chem; 2014 Aug; 22(15):4135-50. PubMed ID: 24980703
[TBL] [Abstract][Full Text] [Related]
51. Potent triazolothione inhibitor of heat-shock protein-90.
Feldman RI; Mintzer B; Zhu D; Wu JM; Biroc SL; Yuan S; Emayan K; Chang Z; Chen D; Arnaiz DO; Bryant J; Ge XS; Whitlow M; Adler M; Polokoff MA; Li WW; Ferrer M; Sato T; Gu JM; Shen J; Tseng JL; Dinter H; Buckman B
Chem Biol Drug Des; 2009 Jul; 74(1):43-50. PubMed ID: 19519743
[TBL] [Abstract][Full Text] [Related]
52. Combining hit identification strategies: fragment-based and in silico approaches to orally active 2-aminothieno[2,3-d]pyrimidine inhibitors of the Hsp90 molecular chaperone.
Brough PA; Barril X; Borgognoni J; Chene P; Davies NG; Davis B; Drysdale MJ; Dymock B; Eccles SA; Garcia-Echeverria C; Fromont C; Hayes A; Hubbard RE; Jordan AM; Jensen MR; Massey A; Merrett A; Padfield A; Parsons R; Radimerski T; Raynaud FI; Robertson A; Roughley SD; Schoepfer J; Simmonite H; Sharp SY; Surgenor A; Valenti M; Walls S; Webb P; Wood M; Workman P; Wright L
J Med Chem; 2009 Aug; 52(15):4794-809. PubMed ID: 19610616
[TBL] [Abstract][Full Text] [Related]
53. Structural and quantum chemical studies of 8-aryl-sulfanyl adenine class Hsp90 inhibitors.
Immormino RM; Kang Y; Chiosis G; Gewirth DT
J Med Chem; 2006 Aug; 49(16):4953-60. PubMed ID: 16884307
[TBL] [Abstract][Full Text] [Related]
54. Discovery of quinolinediones exhibiting a heat shock response and angiogenesis inhibition.
Hargreaves RH; David CL; Whitesell LJ; Labarbera DV; Jamil A; Chapuis JC; Skibo EB
J Med Chem; 2008 Apr; 51(8):2492-501. PubMed ID: 18363347
[TBL] [Abstract][Full Text] [Related]
55. Structure based design of heat shock protein 90 inhibitors acting as anticancer agents.
Doddareddy MR; Thorat DA; Seo SH; Hong TJ; Cho YS; Hahn JS; Pae AN
Bioorg Med Chem; 2011 Mar; 19(5):1714-20. PubMed ID: 21306907
[TBL] [Abstract][Full Text] [Related]
56. A chemical-biological study reveals C9-type iridoids as novel heat shock protein 90 (Hsp90) inhibitors.
Dal Piaz F; Vassallo A; Temraz A; Cotugno R; Belisario MA; Bifulco G; Chini MG; Pisano C; De Tommasi N; Braca A
J Med Chem; 2013 Feb; 56(4):1583-95. PubMed ID: 23362862
[TBL] [Abstract][Full Text] [Related]
57. Macrocyclic lactams as potent Hsp90 inhibitors with excellent tumor exposure and extended biomarker activity.
Zapf CW; Bloom JD; McBean JL; Dushin RG; Nittoli T; Otteng M; Ingalls C; Golas JM; Liu H; Lucas J; Boschelli F; Hu Y; Vogan E; Levin JI
Bioorg Med Chem Lett; 2011 Jun; 21(11):3411-6. PubMed ID: 21515049
[TBL] [Abstract][Full Text] [Related]
58. Design and synthesis of novel macrocyclic 2-amino-6-arylpyrimidine Hsp90 inhibitors.
Suda A; Koyano H; Hayase T; Hada K; Kawasaki K; Komiyama S; Hasegawa K; Fukami TA; Sato S; Miura T; Ono N; Yamazaki T; Saitoh R; Shimma N; Shiratori Y; Tsukuda T
Bioorg Med Chem Lett; 2012 Jan; 22(2):1136-41. PubMed ID: 22192591
[TBL] [Abstract][Full Text] [Related]
59. Discovery of hybrid Hsp90 inhibitors and their anti-neoplastic effects against gefitinib-resistant non-small cell lung cancer (NSCLC).
Jeong CH; Park HB; Jang WJ; Jung SH; Seo YH
Bioorg Med Chem Lett; 2014 Jan; 24(1):224-7. PubMed ID: 24345447
[TBL] [Abstract][Full Text] [Related]
60. NMS-E973, a novel synthetic inhibitor of Hsp90 with activity against multiple models of drug resistance to targeted agents, including intracranial metastases.
Fogliatto G; Gianellini L; Brasca MG; Casale E; Ballinari D; Ciomei M; Degrassi A; De Ponti A; Germani M; Guanci M; Paolucci M; Polucci P; Russo M; Sola F; Valsasina B; Visco C; Zuccotto F; Donati D; Felder E; Pesenti E; Galvani A; Mantegani S; Isacchi A
Clin Cancer Res; 2013 Jul; 19(13):3520-32. PubMed ID: 23674492
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
